At the end of the experiments, the mean tumor quantities were significantly smaller in lenvatinib and losartan-treated mice than in those treated by either single agent. AT-II-stimulated production of vascular endothelial growth factor-A (VEGF-A) and interleukin-8 and suppressed lenvatinib-mediated autocrine VEGF-A production in HCC cells. Moreover, it directly inhibited VEGF-mediated endothelial cell growth. Notably, the…